Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2020

01-09-2020 | Breast Cancer | Correction

Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer

Authors: Ahrong Ham, Min Hwan Kim, Gun Min Kim, Jee Hung Kim, Jee Ye Kim, Hyung Seok Park, Seho Park, Young Up Cho, Byeong Woo Park, Seung Il Kim, Joohyuk Sohn

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Login to get access

Excerpt

In the original publication of the article, under the Results section, subheading “Patient survival”, the second sentence that reads as “The 6-month PFS was 92.4%, 81.8%, and 93.3% and the 1-year PFS was 72.0%, 88.9%, and 78.9% in Groups 1–3, respectively.” should read as "The 6-month PFS was 82.8%, 75.0%, and 68.0% and the 1-year PFS was 77.0%, 62.0%, and 63.8% in Groups 1–3, respectively.". …
Metadata
Title
Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
Authors
Ahrong Ham
Min Hwan Kim
Gun Min Kim
Jee Hung Kim
Jee Ye Kim
Hyung Seok Park
Seho Park
Young Up Cho
Byeong Woo Park
Seung Il Kim
Joohyuk Sohn
Publication date
01-09-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05796-y

Other articles of this Issue 2/2020

Breast Cancer Research and Treatment 2/2020 Go to the issue

Epidemiology

Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study

Clinical trial

Assessing preferences for receiving supportive care resources among patients seen at a Breast Care Center

Clinical trial

Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer

Epidemiology

Racial differences in the relationship between surgical choice and subsequent patient-reported satisfaction outcomes among women with early-stage hormone-positive breast cancer

Review

Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound

Letter to the Editor

Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits